Turn Therapeutics Inc. Common Stock (TTRX) Stock Price
TTRXStock
$10.57+87.41%52W
Market Cap$320.99M
P/E—
PEG Ratio—
Div yield—
Beta0.20
TTRX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)202.82%
Price vs S&P 500 (4W)-29.77%
VGM Score86.36
TTRX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.02 | -$0.20 | -900.00%(-$0.18) | |
| Q1 2026 | -$0.02 | -$0.04 | -102.00%(-$0.02) |
TTRX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.25
4.25
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
TTRXTurn Therapeutics Inc. Common Stock | — | — | A | — | — | — | — | $10.57 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Turn Therapeutics Inc. Common Stock
Turn Therapeutics is a clinical-stage biotechnology company developing treatments for dermatology, wound care, and infectious diseases. The company's proprietary PermaFusion platform enhances drug stability and bioavailability, enabling lower doses and reduced side effects. Its lead programs target moderate to severe eczema and onychomycosis.